SGS launches new large molecule bioanalytical services
Investment builds on company's expertise in small molecule analysis and the use of LC/MS-MS techniques.
SGS is now offering clients large molecule bioanalytical services at its laboratory in Wavre, Belgium. The facility has invested in new and dedicated LC/MS-MS instruments and is currently validating internal methods within the laboratory, ensuring that services will be available by the end of 2017.
The investment includes the installation of Sciex instruments, and the introduction of supporting Sciex BioBA sample preparation kits. This will allow the laboratory to handle the analysis of a wide range of samples, including peptides, proteins and complex biological molecules, such as monoclonal antibodies. Initially, the service will focus on pre-clinical samples, with the aim of rapidly expanding this to analytical methods used for clinical studies.
Bernard Jeanbaptiste, Bioanalysis Manager for SGS Belgium, said: “Our laboratory at Wavre has a rich history and expertise in small molecule analysis and the use of LC/MS-MS techniques. As a result, this investment is a natural progression of our capabilities, enabling us to serve the growing market for large molecule analysis and characterization. The investment will bring value to clients and support our current activities in large molecule bioanalysis across the global SGS network.”
SGS’s Wavre 8,400 m2 laboratory, on the outskirts of Brussels, provides a wide range of services to clients around the world, including method development and validation, analytical chemistry, microbiological testing, potency assays and cell line characterization.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...